| John D Serini, DO | |
|
2093 Health Dr Sw, Suite 101, Wyoming, MI 49519-9691 | |
| (616) 828-5727 | |
| (616) 828-5726 |
| Full Name | John D Serini |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 47 Years |
| Location | 2093 Health Dr Sw, Wyoming, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285679589 | NPI | - | NPPES |
| 4819265 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 5101007294 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Metro Health Hospital | Wyoming, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gastroenterology Consultants Plc | 9638190812 | 2 |
News Archive
Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.
Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.
Kaiser Foundation Hospitals, Kaiser Foundation Health Plan, Inc., and their respective subsidiaries (KFH/HP) reported today a combined total operating revenue of $11.9 billion for the quarter ending September 30, 2011, compared to $11.1 billion in the same period in 2010.
GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.
Fluidigm Corporation announced today a collaboration with BD Biosciences, a segment of BD, to co-host a public seminar series on the isolation and analysis of single cells. Entitled A Powerful Technique for Single-Cell Analysis, the public seminar series will showcase cell isolation using the BD FACSAria III Cell Sorter and analysis using the Fluidigm BioMark HD System.
› Verified 6 days ago
| Entity Name | Gastroenterology Consultants Plc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861526196 PECOS PAC ID: 9638190812 Enrollment ID: O20051215000369 |
News Archive
Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.
Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.
Kaiser Foundation Hospitals, Kaiser Foundation Health Plan, Inc., and their respective subsidiaries (KFH/HP) reported today a combined total operating revenue of $11.9 billion for the quarter ending September 30, 2011, compared to $11.1 billion in the same period in 2010.
GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.
Fluidigm Corporation announced today a collaboration with BD Biosciences, a segment of BD, to co-host a public seminar series on the isolation and analysis of single cells. Entitled A Powerful Technique for Single-Cell Analysis, the public seminar series will showcase cell isolation using the BD FACSAria III Cell Sorter and analysis using the Fluidigm BioMark HD System.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John D Serini, DO 2093 Health Dr Sw, Suite 101, Wyoming, MI 49519-9691 Ph: (616) 828-5727 | John D Serini, DO 2093 Health Dr Sw, Suite 101, Wyoming, MI 49519-9691 Ph: (616) 828-5727 |
News Archive
Nuvilex, Inc. announced its plans to continue development of the live-cell encapsulation technology obtained with its recent acquisition of SG Austria, to carry out the pancreatic cancer clinical trial, to maintain and expand customers utilizing the encapsulation technology, and to establish itself as an active participant in the stem cell arena. The stem cell market was estimated to be $21.5 billion globally in 2010 and is forecast to reach $63.8 billion by 2015.
Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.
Kaiser Foundation Hospitals, Kaiser Foundation Health Plan, Inc., and their respective subsidiaries (KFH/HP) reported today a combined total operating revenue of $11.9 billion for the quarter ending September 30, 2011, compared to $11.1 billion in the same period in 2010.
GenVec, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic cancer.
Fluidigm Corporation announced today a collaboration with BD Biosciences, a segment of BD, to co-host a public seminar series on the isolation and analysis of single cells. Entitled A Powerful Technique for Single-Cell Analysis, the public seminar series will showcase cell isolation using the BD FACSAria III Cell Sorter and analysis using the Fluidigm BioMark HD System.
› Verified 6 days ago
Mark J Tieszen, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5900 Byron Center Ave Sw, Wyoming, MI 49519 Phone: 616-252-7200 | |
William Marc Katz, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 2093 Health Dr Sw, Ste 200, Wyoming, MI 49519 Phone: 616-459-3158 Fax: 616-819-2222 | |
Dr. Matthew J Spousta, DO Gastroenterology Medicare: Medicare Enrolled Practice Location: 5900 Byron Center Ave Sw, Wyoming, MI 49519 Phone: 616-252-7200 Fax: 616-252-4953 | |
Dr. Srinivas Reddy Mummadi, MBBS Gastroenterology Medicare: Medicare Enrolled Practice Location: 2122 Health Dr Sw, Wyoming, MI 49519 Phone: 616-252-5220 Fax: 616-252-5770 | |
Kurt Koepnick, MD Gastroenterology Medicare: Medicare Enrolled Practice Location: 6105 Wilson Ave Sw, Suite 202, Wyoming, MI 49418 Phone: 616-267-7220 | |
Dr. John Allen Key, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5900 Byron Center Ave Sw, Wyoming, MI 49519 Phone: 616-241-2333 Fax: 616-452-6767 | |
Danielle Light, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5900 Byron Center Ave Sw, Wyoming, MI 49519 Phone: 616-252-7200 |